Glycemicon AG is a Swiss biotechnology company developing novel foods (nutraceuticals) for the maintenance of normal blood sugar levels and better weight management, using new approaches that were initially identified at the ETH Zurich. The lead product’s active substance is naturally occurring in food products as well as in both humans and pets. By improving the functionality of the fat tissue, the active substance improves the insulin sensitivity and enables the body to maintain a healthy blood sugar level.